Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Immunic Inc (IMUX)

Immunic Inc (IMUX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 247,266
  • Shares Outstanding, K 26,249
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,020 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.20
Trade IMUX with:

Options Overview

Details
  • Implied Volatility 78.12%
  • Historical Volatility 52.23%
  • IV Percentile 5%
  • IV Rank 15.10%
  • IV High 135.17% on 03/08/21
  • IV Low 67.97% on 08/27/21
  • Put/Call Vol Ratio 0.42
  • Today's Volume 17
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 233
  • Open Int (30-Day) 431

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.80
  • Number of Estimates 5
  • High Estimate -0.59
  • Low Estimate -0.94
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.87 +6.20%
on 08/20/21
10.48 -10.11%
on 09/03/21
-0.22 (-2.28%)
since 08/17/21
3-Month
7.69 +22.50%
on 08/05/21
14.00 -32.71%
on 07/06/21
-3.89 (-29.23%)
since 06/17/21
52-Week
7.69 +22.50%
on 08/05/21
28.21 -66.61%
on 02/16/21
-8.47 (-47.34%)
since 09/17/20

Most Recent Stories

More News
Immunic, Inc. to Participate in Investor and Scientific Conferences in September

/PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced...

IMUX : 9.42 (-2.99%)
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

/PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced...

IMUX : 9.42 (-2.99%)
Immunic, Inc. to Participate in Investor Conferences in August

/PRNewswire/ -- (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases,...

IMUX : 9.42 (-2.99%)
Immunic, Inc. Announces Closing of $45.0 Million Public Offering

/PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory...

IMUX : 9.42 (-2.99%)
Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

/PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory...

IMUX : 9.42 (-2.99%)
Immunic, Inc. Announces Proposed Public Offering of Common Stock

/PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory...

IMUX : 9.42 (-2.99%)
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORt Inverse Agonist

/PRNewswire/ -- (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases,...

IMUX : 9.42 (-2.99%)
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

/PRNewswire/ -- a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food...

IMUX : 9.42 (-2.99%)
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

/PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced...

IMUX : 9.42 (-2.99%)
Immunic, Inc. to Participate in Industry and Investor Conferences in June

/PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced...

IMUX : 9.42 (-2.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 10.27
2nd Resistance Point 10.10
1st Resistance Point 9.76
Last Price 9.42
1st Support Level 9.25
2nd Support Level 9.08
3rd Support Level 8.74

See More

52-Week High 28.21
Fibonacci 61.8% 20.37
Fibonacci 50% 17.95
Fibonacci 38.2% 15.53
Last Price 9.42
52-Week Low 7.69

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar